STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

USANA (NYSE: USNA) Chief Sales Officer reports sale of 873 shares

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

USANA Health Sciences Inc. insider reports small stock sale. The company’s Chief Sales Officer filed a Form 4 disclosing the sale of 873 shares of USANA common stock on 12/10/2025. The shares were sold at a price of $21 per share, using transaction code “S,” which indicates an open market or private sale.

After this transaction, the officer beneficially owns 8,387 shares of USANA common stock in direct ownership. The filing is made by a single reporting person and does not report any derivative securities activity.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mulham David Mulham

(Last) (First) (Middle)
3838 WEST PARKWAY BLVD

(Street)
SALT LAKE CITY UT 84120

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
USANA HEALTH SCIENCES INC [ USNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF SALES OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/10/2025 S 873 D $21 8,387 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Joshua Foukas, Attorney-in-Fact 12/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did USANA (USNA) disclose in this Form 4?

The Chief Sales Officer of USANA Health Sciences Inc. reported selling 873 shares of USANA common stock on 12/10/2025 at a price of $21 per share.

Who is the reporting person in this USANA (USNA) Form 4 filing?

The reporting person is an officer of USANA Health Sciences Inc., serving as the company’s Chief Sales Officer.

How many USANA (USNA) shares does the insider own after the reported sale?

Following the reported transaction, the officer beneficially owns 8,387 shares of USANA common stock in direct ownership.

What does transaction code "S" mean in the USANA (USNA) Form 4?

Transaction code "S" in a Form 4 indicates a sale of securities, typically through an open market or private transaction.

Does this USANA (USNA) Form 4 report any derivative securities?

No. The section for derivative securities shows no reported acquisitions or dispositions in this filing.

Is the USANA (USNA) Form 4 filed by one or multiple reporting persons?

The document indicates that the Form 4 is filed by one reporting person, not by a group.
Usana Health Sciences Inc

NYSE:USNA

USNA Rankings

USNA Latest News

USNA Latest SEC Filings

USNA Stock Data

381.52M
10.42M
42.93%
61.22%
3.86%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States
SALT LAKE CITY